For Licensing Teams

The IP pipeline your licensing team has never seen.

Lattice indexes every U.S. pharma patent — claims, abstracts, and assignment data — and ranks results by how closely they match what you’re looking for.

U.S. pharma patent corpusClaim-level matchingRanked by semantic relevance
app.latticelicensing.com/search
GLP-1 receptor agonists for cardiometabolic disease
CPC A61K · A61PGrant year 2019–2024Assignee AnyStatus Active
312 patents · ranked by semantic relevancesort: relevance ↓
96
similar
GLP-1/GIP dual agonist with extended half-life for type 2 diabetes
Mar 14, 2024 | Eli Lilly and Company | US 11,842,019 B2
96% similar | Matched in: Claim

“A selective dual agonist of GLP-1 and GIP receptors comprising a fatty-acid acyl moiety conferring once-weekly subcutaneous dosing in human subjects with type 2 diabetes mellitus…”

91
similar
Bispecific anti-PD-L1/VEGF antibody for solid tumor immunotherapy
Sep 4, 2023 | Regeneron Pharmaceuticals | US 11,517,602 B2
91% similar | Matched in: Abstract

“A recombinant bispecific binding molecule that simultaneously engages programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor A (VEGF-A) for the treatment of advanced solid tumors…”

84
similar
mRNA lipid-nanoparticle formulation for personalized neoantigen cancer vaccines
Jul 12, 2022 | Moderna, Inc. | US 10,968,211 B2
84% similar | Matched in: Description

“An ionizable cationic lipid composition encapsulating in vitro-transcribed messenger RNA encoding tumor-associated neoantigens, formulated as a lipid nanoparticle for intramuscular administration…”

~40K
U.S. pharma patents granted every year. The asset that fits your pipeline is in there — unranked, in among the rest.
Seconds
From a plain-language query to a ranked shortlist of claim-level matches, with owner and licensing status attached.

Patent search rewards whoever guesses the right keywords.

That leaves real value buried — assets described in different language, filed under an adjacent CPC code, or held by an owner you weren’t watching.

Lattice searches by meaning. Every claim, abstract, and description is embedded and ranked by semantic relevance, with the current owner and licensing status on every result.

Three steps from pipeline gap to licensable IP.

Query in plain language, claim text, or structured filters. Lattice understands all three.

01

Describe your pipeline gap

Query by therapeutic area, mechanism, target, or claim language — natural language or structured filters work the same way.

02

Lattice surfaces ranked IP

Patent- and claim-level results scored by semantic relevance — each with current-owner and licensing-status signals, across every pharma assignee in the corpus.

03

Route to the current owner

Each result lists the current owner and inventor, with the licensing-status read. Follow up via the patent number — in-platform introductions land in 2026.

Every patent, connected to your pipeline.

Lattice doesn’t just return a list — it maps the relationships between your technology areas, the approaches that address them, the institutions that own them, and the patents that link it all. Hover any node to trace its connections.

Pipeline gap Technology area Top-ranked patent Other patent Institution Approach

Not another catalog. Not another consultant.

Catalogs show landscapes; Lattice shows licensable patents. Brokers work mandates; Lattice runs continuously across the same pharma corpus, every day.

Lattice vs. Catalogs

PatSnap · Cortellis · PitchBook
LatticeCatalogs
Resolution
Patent & claim-level matching
Landscape overviews
Ownership
Current owner + licensing-status signals
Static, often-stale assignee
Matching
Ranked by your profile, semantically
Keyword & manual filtering
Cost
Per-seat subscription
$50K–$250K / yr

Lattice vs. Brokers

Yet2 · scouts · in-house BD
LatticeBrokers
Scale
Continuous, platform-indexed
Project-by-project
Coverage
Entire U.S. pharma patent corpus
Personal rolodex
Speed
Results in minutes
8–12 week cycles
Transparency
Every ranked result, with why
Broker-curated shortlist
Join the Pilot

Search the pharma IP your competitors can’t surface.

We’re onboarding a small group of licensing, BD, and IP teams for early access — semantic search across every U.S. pharma patent, with current-owner and licensing-status data on each result.

Free during the pilot · No credit card
Lattice — University IP for Pharma Licensing